Bill Oxford
Trinity Biotech (NASDAQ:TRIB) stock shot up 44% in post-market buying and selling Monday after the diagnostics firm increased its 2024 gross sales steerage and stated it was ramping up manufacturing capacity.
Trinity stated that as a result of increased demand, it has expanded manufacturing capacity for its TrinScreen HIV check and raised its 2024 gross sales forecast for the product to $10M from $8M.
The firm has additionally increased manufacturing capacity for its FlexTrans viral transport medium as a result of an anticipated improve in demand on account of the mpox outbreak, in keeping with a press release.
The World Health Organization just lately declared mpox, also called monkeypox, a public well being emergency of worldwide concern amid the emergence of a extra simply transmissible variant of the virus.
Mpox vaccine builders embrace Tonix Pharmaceuticals (TNXP), Bavarian Nordic (OTCPK:BVNKF) (OTCPK:BVNRY) and GeoVax Labs (GOVX), whereas Emergent Biosciences (EBS) has an accredited vaccine and remedy for smallpox, a associated illness.
Providers of mpox check services and products embrace LabCorp (LH), Quest Diagnostics (DGX), Co-Diagnostics (CODX), Roche (OTCQX:RHHBY), Abbott Laboratories (ABT) and Applied DNA Sciences (APDN).
Source: Seekingalpha
